This appraisal (ID1536) is a review of pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy (TA519) following data collection via a managed access agreement. Patient access according to the terms of TA519 is unaffected by the draft recommendations of ID1536 while the review is ongoing.